A compound represented by the formula: wherein R.sup.1 is a 5- or 6-membered ring; R.sup.3 is a hydrogen atom, a lower alkyl group or a lower alkoxy group; R.sup.7 and R.sup.8 are each a hydrogen atom or a lower alkyl group; Z.sup.1 is another 5- or 6-membered aromatic ring; Z.sup.2 is a group represented by -Z.sup.2a-W.sup.1-Z.sup.2b- [wherein Z.sup.2a and Z.sup.2b are each O, S(O).sub.m (wherein m is 0, 1 or 2), an imino group or a bond, and W.sup.1 is an alkylene chain]; X is CR (wherein R is a hydrogen atom, a lower alkyl group, a lower alkoxy group, an acyl group, or R and adjacent R.sup.4 may form a 5- or 6-membered alicyclic heterocyclic group) or N; R.sup.4 is NR.sup.5R.sup.6 (wherein R.sup.5 and R.sup.6 are each a hydrogen atom, a hydrocarbon group, a heterocyclic group or an acyl group), or R.sup.5 and R.sup.6 are bonded to each other to form a heterocyclic group of NR.sup.5R.sup.6; and R.sup.2 is (1) an amino group which may be a quaternary ammonium or oxide, (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or the like; or a salt thereof. The compound has excellent CCR5 antagonistic activity and thus is useful as a prophylactic and/or therapeutic medicine for HIV infection into human peripheral blood monocyte, especially for AIDS.